Navigation Links
Novel therapeutic targets identified for small cell lung cancer
Date:9/6/2012

PHILADELPHIA Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the results of a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

Currently, small cell lung cancer accounts for about 15 percent of lung cancer diagnoses in the United States. Patients with the disease will initially respond to chemotherapy, but almost all will have disease recurrence within a couple of months, according to Lauren A. Byers, M.D., assistant professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.

"Unlike nonsmall cell lung cancer [NSCLC], where there have been new targeted drugs developed in the last ten years, the only currently approved treatments for small cell lung cancer are cytotoxic chemotherapies," Byers said. "Because most targeted therapies directly act on proteins, identifying if certain proteins are overexpressed in small cell lung cancer could have therapeutic applications."

In order to identify molecular differences between NSCLC and the more aggressive small cell lung cancer, Byers and colleagues used tools called reverse phase protein arrays. These allow the examination of the expression of about 200 proteins that are in key signaling pathways known to be involved in driving cancer growth.

"We discovered that small cell lung cancer and NSCLC have dramatically different protein profiles in terms of which proteins are 'turned on' and are driving the behavior of these cancers," Byers said. "In small cell lung cancer, proteins that were present at higher levels included several DNA repair proteins such as PARP1 and a protein involved in cancer stem cell renewal, EZH2."

PARP1 was further evaluated as a target for treatment of small cell lung cancer because there are several PARP inhibitors in advanced-stage clinical trials for other tumor types such as breast and ovarian cancers. Moreover, small cell lung cancer is sensitive to platinum-based chemotherapy, and PARP inhibitors have shown increased activity when used on other platinum-sensitive tumors.

Two PARP inhibitors were tested on small cell lung cancer cell lines alone and in combination with standard frontline chemotherapeutics, cisplatin and etoposide, or another commonly used chemotherapeutic, irinotecan. The inhibitors slowed the growth of small cell lung cancer cells, but not non-neuroendocrine NSCLC cells, according to the study. In addition, levels of PARP1 expression directly correlated with PARP inhibitor sensitivity.

As with many targeted drugs, it is possible that combining PARP inhibitors with other targeted drugs may significantly improve efficacy, according to Byers.

"Our next step is to begin to examine the use of PARP inhibitors in combination with other drugs in preclinical and clinical investigations of small cell lung cancer," she said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Novel technique demonstrates interactions between malaria parasite and HIV
2. Genetic analyses reveal novel mutations as causes of startle disease
3. UNC team describes novel inflammatory protein function
4. Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases
5. LA BioMed investigator, Dr. Yutaka Niihara, developing novel cellular therapy
6. New method to find novel connections from gene to gene, drug to drug and between scientists
7. Novel pig model may be useful for human cancer studies
8. Novel anti-malarial drug target identified
9. ICAP study uses novel incentive to encourage HIV patient care and treatment
10. Researchers to use novel metabolomics technology for COPD
11. Cell differentiation as a novel strategy for the treatment of an aggressive type of skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... U.S. Security Associates (USA) was named ... their industry leading training methods that engage their associates and link their achievements ... elite in employer-sponsored training and development programs. , “The 2017 Training Top 125 ...
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 hardcover ... Lithuanian language and its poetry inspired him in writing “ Forest Lungs ... aspects of a living, breathing forest where nothing ever stays the same. His subjects ...
(Date:12/5/2016)... ... 05, 2016 , ... “Epilepsy Awareness,” which can be found ... a conversation about epilepsy, bearing down on the social stigma and lack of ... with epilepsy within their lifetime. With such a large percentage of people affected, ...
(Date:12/5/2016)... , ... December 05, 2016 , ... BSI and Brenntag ... United States and Canada for distribution of their natural fruits and beverage ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... portfolio company, today announced it has acquired the assets of Frankfurt, Germany ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016 Special purpose needles are used in ... fluid and cells from organs or lumps and are available ... The global market for special purpose needles is showing a ... of revenue, the global special purpose needles market is projected ... period (2016–2026) and is expected to be valued at US$ ...
(Date:12/5/2016)... Dec. 5, 2016  Pennsylvania Physician General Dr. ... Programs Gary Tennis today filled prescriptions for ... Pharmacy in York to demonstrate ... Dr. Levine as a prescription to acquire naloxone at ... important to remember that any Pennsylvanian can walk up ...
(Date:12/5/2016)... -- Research and Markets has announced the addition ... (Biomedical & Biochemical Research, Disease Diagnostics), End User (Academic & Research ... report to their offering. ... , The western blotting ... USD 574.8 Million in 2016, growing at a CAGR of 4.9%. ...
Breaking Medicine Technology: